Research Guide · GLOW70

What is GLOW70?

A tri-peptide research composite combining GHK-Cu, BPC-157 and TB-500 for multi-pathway tissue repair, dermal regeneration and angiogenesis research.

Updated September 2026 Research Use Only 11 min read

What is GLOW70

A 70mg three-component peptide composite combining complementary tissue-repair peptides into one formulation for multi-pathway research models.

Composite Formulation

GLOW70 (CP-3 designation = composite of three) is a research composite delivering 70mg total of three peptides in a single vial: GHK-Cu (copper tripeptide), BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4 fragment). It is designed as a multi-pathway tissue repair research composite.

Mechanistic Rationale

The three peptides target complementary tissue-repair pathways: GHK-Cu drives collagen synthesis and copper-dependent regenerative signalling; BPC-157 promotes angiogenesis via VEGF and accelerates GI/tendon repair; TB-500 enables cellular migration via G-actin sequestration. Combined research investigation of these parallel mechanisms aims to model multi-pathway tissue restoration in dermal, musculoskeletal and visceral repair contexts.

Research Status

For in-vitro laboratory research and animal model studies only. Not approved for human consumption or therapeutic application. The composite formulation is a vendor-specific research convenience and is not derived from any pharmaceutical or clinical product.

Component Mechanisms

Each component contributes a distinct molecular pathway to the overall composite research profile.

GHK-Cu — Copper Tripeptide Signalling

GHK (glycyl-L-histidyl-L-lysine) bound to copper(II) is a 526 Da naturally occurring tripeptide. It modulates collagen synthesis by upregulating COL1A1/COL1A2 transcription, normalises matrix metalloproteinase (MMP) activity, exerts antioxidant effects through copper-dependent SOD-like activity, and stimulates angiogenesis. Foundational research by Pickart established its role in skin remodelling and wound repair (Pickart et al., 2012).

BPC-157 — Angiogenesis & Cytoprotection

A 15-amino acid pentadecapeptide derived from a protective sequence of human gastric juice. Promotes angiogenesis through VEGF upregulation and nitric oxide synthase modulation; accelerates tendon-to-bone healing, gut barrier repair, and exerts neuroprotective effects via dopaminergic system interactions in animal models (Sikiric et al., 2012; Sikiric et al., 2014).

TB-500 — Cellular Migration via Actin Sequestration

A 17-amino acid synthetic fragment of the larger Thymosin Beta-4 protein, containing the active actin-binding domain. Sequesters G-actin monomers, regulating cellular cytoskeletal dynamics that enable cell migration to injury sites, recruitment of progenitor cells, and modulation of inflammatory cytokine balance (Crockford et al., 2010; Goldstein et al., 2012).

Combined Pathway Synergy

In repair models, TB-500 first recruits progenitor cells to the injury site; BPC-157 establishes local angiogenic conditions; GHK-Cu drives collagen deposition and remodelling. The three pathways are temporally and mechanistically complementary — recruitment, vascularisation, and matrix synthesis — providing a research model for multi-target repair pharmacology distinct from single-peptide protocols.

GLOW70 vs Related Composites

Comparison with TR-2, TR-3, KLOW80, and single-peptide protocols.

Composite

Components

Distinguishing Focus

GLOW70 (CP-3)

GHK-Cu + BPC-157 + TB-500 (70mg)

Dermal regeneration & multi-pathway tissue repair with copper signalling

TR-2

BPC-157 + TB-500 (20-40mg)

Dual-peptide tissue repair without copper or anti-inflammatory components

TR-3

TB-500 + BPC-157 + KPV (30mg)

Adds KPV anti-inflammatory NF-κB inhibition; substitutes KPV for GHK-Cu

KLOW80

GHK-Cu 50mg + TB-500 + BPC-157 + KPV (10mg each)

Four-component composite with GHK-Cu dominant + KPV anti-inflammatory addition

Single-peptide

One peptide alone

Pathway isolation; cleaner mechanistic dissection but no multi-target synergy

Research Context: GLOW70 is positioned as the dermal-focused composite (with GHK-Cu’s collagen/copper signalling) without the broader anti-inflammatory KPV component found in TR-3 and KLOW80. For research models prioritising skin regeneration and dermal repair, GLOW70 offers convenient three-pathway delivery; researchers needing inflammation modulation may prefer TR-3 or KLOW80.

Key Research Applications

Primary research domains for the GLOW70 composite.

Dermal Regeneration & Anti-Ageing Skin Models

GHK-Cu’s established role in collagen synthesis combined with TB-500/BPC-157 vascularisation makes GLOW70 attractive for in-vitro dermal regeneration assays — fibroblast cultures, ex-vivo skin explants, and rodent wound-healing models exploring photoaged or chronologically aged skin recovery.

Wound Healing & Scar Reduction

In rodent excisional and incisional wound models, the composite addresses three rate-limiting steps: cellular recruitment (TB-500), vascularisation (BPC-157), and remodelling (GHK-Cu). Research outcomes include accelerated wound closure rates, reduced scar tissue thickness, and improved tensile strength versus single-peptide controls.

Hair Follicle Regeneration Research

All three peptides have published evidence supporting hair follicle modulation: GHK-Cu enhances dermal papilla cell proliferation; TB-500 contributes to follicle stem cell migration; BPC-157 supports follicle vascularisation. Combined, the composite is studied in androgenetic and inflammatory alopecia models.

Tendon & Ligament Repair

BPC-157 and TB-500 have established preclinical literature for tendon-to-bone healing and ligament repair. GHK-Cu’s collagen-modulating effects complement these by enhancing matrix integrity. Research models use the composite to study Achilles transection, rotator cuff repair, and ACL reconstruction healing.

Multi-pathway Repair Pharmacology

As a research tool, GLOW70 enables investigation of how parallel-pathway interventions compare to sequential single-peptide protocols. Important for designing rational combination therapies and understanding which mechanistic axes contribute most to overall repair outcomes.

Quick Reference Specifications

Key parameters for the composite.

P · 01

Designation

GLOW70 CP-3 Composite (Composite of 3)

P · 02

Components

GHK-Cu + BPC-157 + TB-500

P · 03

Total Mass

70mg per vial (lyophilised)

P · 04

Component MWs

GHK-Cu ~402 Da; BPC-157 ~1,419 Da; TB-500 ~889 Da

P · 05

Component CAS Numbers

GHK-Cu 89030-95-5; BPC-157 137525-51-0; TB-500 (Tβ4 17–23 fragment) 885340-08-9

P · 06

Purity

>99% HPLC per component

P · 07

Format

Lyophilised composite powder

P · 08

Mechanism Profile

Multi-pathway: collagen synthesis + angiogenesis + cellular migration

P · 09

Storage (Lyophilised)

2–8°C; protect from light; long-term stable

P · 10

Storage (Reconstituted)

2–8°C with bacteriostatic water; stable 2–4 weeks

Reconstitution & Storage

Handling guidance for multi-peptide composites.

Reconstitution

Reconstitute with sterile bacteriostatic water (0.9% NaCl with 0.9% benzyl alcohol). Use sterile syringes and gentle dissolution; avoid shaking. Multi-peptide composites require slightly longer dissolution times (3–5 minutes gentle swirling) than single-peptide preparations.

Storage Timeline

Reconstituted GLOW70 maintains bioactivity for 2–4 weeks at 2–8°C. The copper-bound GHK-Cu component can drive trace catalytic effects, so protect rigorously from light and minimise repeated air exposure during withdrawals.

Quality Control

Reconstituted solution should be clear with a faint blue-green tint from the GHK-Cu copper complex. Cloudiness, precipitate, brown discolouration, or strong colour change indicates degradation or copper precipitation; discard.

Handling Best Practices

Maintain consistent refrigeration; document reconstitution date; aliquot for extended programmes; use fresh sterile needles per withdrawal; never freeze-thaw; equilibrate to room temperature before use; discard solutions older than 4 weeks.

Component Evidence at a Glance

What the published literature supports for each ingredient.

GHK-Cu

Collagen & matrix synthesis

Stimulated collagen synthesis in fibroblasts at nanomolar concentrations; widely reviewed for skin-regeneration pathways. Human data: small topical cosmetic studies.^1–2

BPC-157

Angiogenesis & tendon repair

Rodent tendon, muscle and ischaemia models, including FAK–paxillin and VEGFR2–Akt–eNOS signalling. Human data: a two-participant IV safety pilot (2025).^3–5

TB-500

Cell migration & wound closure

Full-length Tβ4 accelerated re-epithelialisation in rat wounds; the LKKTETQ actin-binding motif used in TB-500 reproduced key pro-angiogenic effects in vitro. No human data for the fragment.^6–8

Regulatory & Research Status

Component status in 2026.

APR 26

FDA Category 2 removal

BPC-157, TB-500 and injectable GHK-Cu were among twelve peptides removed from the US FDA’s Category 2 compounding list. This is not an approval.

JUL 26

Advisory committee votes

The FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend BPC-157 and TB-500 individually for the 503A bulks list. GHK-Cu was not reviewed. The votes are non-binding and do not cover combination products.

SPORT

WADA 2026

BPC-157 (S0) and TB-500 (S2) are prohibited at all times.

Evidence Quality & Limitations

No peer-reviewed study has tested GLOW70 as a combination. The rationale rests on each component’s individual evidence and complementary mechanisms, so “synergy” is a hypothesis to test rather than an established finding. Component ratios reflect the product formulation rather than published dose-response work, and the stability and compatibility of the peptides stored together in one solution have not been characterised in the literature. Nearly all component data are preclinical.

References

Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238:343–6. PubMed
Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PubMed
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PubMed
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–4. PubMed
Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364–8. PubMed
Philp D, et al. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17:2103–5. PubMed
Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. PubMed

⚠ Research Use Only. The compounds discussed in this guide are intended strictly for in-vitro laboratory research. Not for human consumption, therapeutic use, or veterinary application. Researchers must comply with all applicable local regulations.